HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced the positive interim results from a recent Phase II trial of its late-stage drug candidate IPX066 were presented at the 13th International Congress of Parkinson’s Disease (PD) and Movement Disorders in Paris, France. The IPX066 data was presented as part of a plenary session on Parkinson’s disease entitled “Promising New Therapies in Development”.
